Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

A substantial body of evidence supports that the gut microbiota plays a pivotal role in the
regulation of metabolic, endocrine and immune functions. In recent years, there has been …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Importance An association between sleep duration and the trajectory of cognitive decline
has not been conclusively demonstrated. Objective To investigate the association between …

Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized
by cognitive decline and the presence of two core pathologies, amyloid β plaques and …

Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like
peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for …

Introduction More than two-thirds of people with dementia live in low-and middle-income
countries (LMICs), resulting in a significant economic burden in these settings. In this …